In 1986 she graduated from the Faculty of Medicine and in 1988 she graduated from the Department of Dentistry at the Medical University in Poznań.
Since 1991 she has been working at the Institute of Psychiatry and Neurology in Warsaw where in 1997 she has obtained 2nd degree specialisation in Neurology, while in 2000 she obtained the title of Doctor of Medicine.
Currently she is an Assistant Professor at the 1st Neurology Clinic IPiN; for many years she is a member of the Scientific Council of the Institute. Licenced electroencephalography technician (EEG), member of the Polish Neurology Society, Polish Epileptology Society, Polish Society of Clinical Neurophysiology.
Her field of interest is epilepsy, stroke, Alzheimer’s disease. She participated and still participates in numerous scientific projects and clinical studies in the country and abroad.
Participation in clinical trials:
2006-2008 Trail NO 1175 Protocal RPCE04P 1901 UCB Pharma (LVE)
2005-2006 SITS-MOST
2006-2010 IST-3
2008-2013 INTERSTROKE
2008-2010 SCAST
2009-2012 DIAS-3
2014-2015 SOCRATES
2016-1017- GWEP 1330
Connect
Connect trials
ATLAS study
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of ALS but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
PHOENIX trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
ADORE Trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
COURAGE-ALS Trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
APL2-ALS-206 Trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
TUDCA-ALS
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.